On March 8th, at the AAD conference in the United States, the world’s largest real-world study of JAK1 inhibitors, Abrotinib CHnese rRegistry on AD (AHEAD), was recently released internationally. The AHEAD provides more real-world research and medical evidence-based data for the clinical application of innovative small molecule drugs with high selectivity JAK1 inhibitors in the field of atopic dermatitis (AD), further consolidating clinical scientific basis, optimizing treatment strategies, and driving the reshaping of AD diagnosis and treatment pathways.
Scan code to share